News25/Ratings2
Price$0.52-0.30 (-36.70%)
2026-05-222026-08-26
News · 26 weeks50+550%
2026-03-012026-08-23
Mix1790d
- SEC Filings7(41%)
- Insider6(35%)
- Other4(24%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Adagio Medical Holdings IncSCHEDULE 13G/A - Adagio Medical Holdings, Inc. (0002006986) (Subject)
- SECSEC Form 8-K filed by Adagio Medical Holdings Inc8-K - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- SECAdagio Medical Holdings Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- INSIDERSEC Form 4 filed by Director Salmon Sean4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
- INSIDERSEC Form 4 filed by Director Mirsaeedi-Farahani Keyvan4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
- INSIDERSEC Form 4 filed by Director Cox James L4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
- INSIDERSEC Form 4 filed by Director Gardiner Sandra A.4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
- INSIDERSEC Form 4 filed by Director Mishan Orly4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
- INSIDERSEC Form 4 filed by Director Moran Timothy P.4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
- SECSEC Form 10-Q filed by Adagio Medical Holdings Inc10-Q - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- SECAdagio Medical Holdings Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- PRAdagio Medical Reports Second Quarter 2026 ResultsAdagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. Recent Business Highlights: Announced the successful treatment at the Hospital of University of Pennsylvania of the first patient with the Company’s next-generation vCLAS™ Ultra Ultra-Low temperature ablation catheter ("ULTA"), which is designed to be faster and more maneuverable than the first generation vCLAS™ Ventricular Ablation System catheter, under Expanded Access authorization from the U.S. Food and Drug Administration ("FDA") Anno
- PRAdagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA SystemvCLAS Ultra System Designed to Optimize Usability and Workstream to Address Entire Spectrum of Ventricular Tachycardia PatientsAdagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the successful treatment of the first patient with its next-generation vCLAS Ultra Ultra-Low Temperature Ablation ("ULTA") system under Expanded Access authorization from the U.S. Food and Drug Administration ("FDA").The patient, who presented with non-ischemic cardiomyopathy and a recent history of failed radiofrequency ("RF") and coronary venous alcohol ablations to address the ventr
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Adagio Medical Holdings IncSCHEDULE 13G/A - Adagio Medical Holdings, Inc. (0002006986) (Subject)
- SECAmendment: SEC Form 10-K/A filed by Adagio Medical Holdings Inc10-K/A - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- SECAdagio Medical Holdings Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- SECAdagio Medical Holdings Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- SECAdagio Medical Holdings Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- PRAdagio Medical Submits Premarket Approval Application to FDA for vCLAS® Ventricular Ablation System for the Treatment of Ventricular TachycardiaPMA Submission Supported by FULCRUM-VT Pivotal Trial Data — 209 Patients Across 20 Leading Centers; Breakthrough Device Designation Previously Granted Marks the First-Ever PMA Submission for a Purpose-Built VT Ablation System in a $5.8B Market Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the submission of its Premarket Approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for the vCLAS Ventricular Ablation System for the treatment of drug-refractory, recurrent, sustained monomorphic ventricular tachycardia ("VT") in patients w
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Adagio Medical Holdings IncSCHEDULE 13G/A - Adagio Medical Holdings, Inc. (0002006986) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Adagio Medical Holdings IncSCHEDULE 13G/A - Adagio Medical Holdings, Inc. (0002006986) (Subject)
- SECSEC Form 10-Q filed by Adagio Medical Holdings Inc10-Q - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- SECAdagio Medical Holdings Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- SECSEC Form DEF 14A filed by Adagio Medical Holdings IncDEF 14A - Adagio Medical Holdings, Inc. (0002006986) (Filer)
- PRAdagio Medical to Participate in the BofA Securities 2026 Health Care ConferenceAdagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the BofA Securities 2026 Healthcare Conference on Wednesday, May 13, 2026 at 4:35pm PDT in Las Vegas. Presentation Information A live webcast and replay of the session will be accessible at https://bofa.veracast.com/webcasts/bofa/healthcare2026/051rbr.cfm or on the Company's website at https://investors.adagiomedical.com. About Adagio Medical Holdings, Inc. Adagio is a medical device company focused on developing and commercializing products for the treatment of c
ADGM FAQ
5 questionsWhere does ADGM stock trade?
Adagio Medical Holdings Inc (ADGM) is listed on NASDAQ.What sector and industry is ADGM in?
Adagio Medical Holdings Inc operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about ADGM?
Adagio Medical Holdings Inc has had 2 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight with a $300.00 price target on 2026-04-14. Recent price targets range from $300.00 to $400.00.What companies are similar to ADGM?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare ADGM side-by-side with any of them on Quantisnow.How can I track ADGM on Quantisnow?
Quantisnow aggregates Adagio Medical Holdings Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADGM to receive live email and push alerts on every new disclosure.